News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
US FDA Staff Backs CSL Behring Clot Disorder Therapy
January 7, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Jan 7 (Reuters) - CSL Ltd's proposed treatment for a rare bleeding disorder appears safe and effective enough to support approval, U.S. drug reviewers said in documents released on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Food and Drug Administration (FDA)
CSL
MORE ON THIS TOPIC
COVID-19
FDA assembles vaccine experts to update COVID-19 formulation
May 27, 2026
·
2 min read
·
Tristan Manalac
Breast cancer
AstraZeneca’s breast cancer pill hit with review delay after negative adcomm vote
May 27, 2026
·
4 min read
·
Tristan Manalac
Regulatory
Makary’s reforms will live on at FDA even as leadership turns over
May 27, 2026
·
2 min read
·
Tristan Manalac
Podcast
Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds
May 27, 2026
·
2 min read
·
Jef Akst
